Table 5.
Laboratory findings before and after ezetimibe treatments in men
| Baseline | 24 weeks | P-value (95% CI) | |
|---|---|---|---|
| AST (IU/L) | 26.4 ± 12.9 | 25.8 ± 9.2 | 0.405 |
| ALT (IU/L) | 27.9 ± 16.2 | 27.5 ± 13.7 | 0.452 |
| γ-GTP (IU/L) | 68.2 ± 90.6 | 58.2 ± 75.6 | 0.294 |
| CPK (IU/L) | 151.6 ± 74.3 | 148.4 ± 87.1 | 0.429 |
| BUN (mg/dL) | 16.3 ± 4.9 | 17.1 ± 4.5 | 0.222 |
| Creatinine (mg/dL) | 0.88 ± 0.25 | 0.90 ± 0.26 | 0.362 |
| Uric acid (mg/dL) | 6.35 ± 1.22 | 6.48 ± 1.55 | 0.337 |
| Triglycerides (mg/dL)* | 172.4 (52–376) | 143.9 (56–777) | 0.006 (−14.4 to 65.4) |
| HDL-cholesterol (mg/dL) | 46.5 ± 10.5 | 47.3 + 11.5 | 0.372 |
| Non HDL-cholesterol (mg/dL) | 185.5 ± 95.6 | 139.3 ± 30.7 | 0.002 |
| LDL-cholesterol (mg/dL) | 128.1 ± 36.2 | 106.0 ± 29.8 | 0.002 |
| Fasting plasma glucose (mg/dL) | 108.5 ± 28.5 | 106.4 ± 26.7 | 0.366 |
| Hemoglobin Alc (%) | 5.7 ± 1.1 | 5.6 ± 0.7 | 0.312 |
| Insulin (μU/mL)* | 15.6 (2.7–119.2) | 7.8 (2.4–49.4) | 0.002 (−3.27 to 9.52) |
| HOMA-IR* | 6.00 (0.68–40.2) | 2.14 (0.53–14.2) | 0.001 (−1.43 to 5.02) |
| White blood cell count (×102/mm3) | 6358 ± 1438 | 5966 ± 1185 | 0.091 |
| Hemoglobin (g/dL) | 15.0 ± 1.4 | 15.0 ± 1.6 | 0.500 |
| Platelet (×104/mm3) | 22.3 ± 4.1 | 22.8 ± 4.6 | 0.302 |
| High sensitivity CRP (mg/dL)* | 0.09 (0.011–1.200) | 0.07 (0.010–1.000) | 0.132 (−0.05 to 0.12) |
| RLP-c (mg/dL)* | 5.15 (1.6–18.9) | 6.11 (1.9–45.3) | 0.376 (−3.12 to 3.42) |
| Free fatty acid (mEq/L) | 0.53 ± 0.28 | 0.47 ± 0.23 | 0.146 |
*
Data are means ± standard deviation, geometric mean and range. These variables are shown in the original scale after analysis using log (natural)-transformed values.
γ-GTP, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, asparatate aminotransferase; BUN, blood urea nitrogen; CI, confidence interval; CPK, creatine phosphokinase; CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; RLP-c, remnant-like particle cholesterol.